Hawley JE, Pan S, Kandadi H, et al. - This study was carried out to analyze circulating immune biomarkers by race in men with metastatic castration-resistant prostate cancer treated with sipuleucel-T. In this study, circulating immune markers from 54 men (18 Black and 36 White men) were compared with metastatic castrate-resistant prostate cancer who received sipuleucel-T and were enrolled on an immune monitoring registry. There were no differences by race in either the antigen-specific T cell response or in the humoral responses to the immunizing antigen PA2024 and select secondary antigens.